Novo Nordisk A/S
NVO66.400USD
+1.240+1.90%
收盘 04/30, 16:00（美东）报价延迟15分钟
223.50B总市值
15.25市盈率 TTM
关于 Novo Nordisk A/S 公司
Novo Nordisk A/S 是一家从事糖尿病护理的全球医疗保健公司。该公司还从事医药产品的发现、开发、制造和营销。该公司通过两个业务部门运营：糖尿病和肥胖护理以及生物制药。该公司的糖尿病和肥胖护理部门涵盖胰岛素、GLP-1、其他蛋白质相关产品（如胰高血糖素）、蛋白质相关输送系统和针头以及口服抗糖尿病药物。该公司的生物制药部门涵盖血友病护理、生长激素治疗和激素替代疗法等治疗领域。该公司还提供用于治疗肥胖症的 Saxenda 产品。它提供一系列产品，包括 NovoLog/NovoRapid；NovoLog Mix/NovoMix；Prandin/NovoNorm；NovoSeven；Norditropin 和 Vagifem。截至 2016 年 12 月 31 日，该公司的产品销往 180 多个国家。其区域结构由两个商业部门组成：北美和国际运营。
公司简介
公司代码NVO
公司名称Novo Nordisk A/S
上市日期May 17, 1974
成立日期1931
CEOMr. Lars Fruergaard Joergensen
员工数量76302
证券类型Ordinary Share
年结日May 17
公司地址Novo Alle 1
城市BAGSVAERD
上市交易所The Toronto Stock Exchange
国家Denmark
邮编2880
电话4544448888
网址https://www.novonordisk.com/
公司代码NVO
上市日期May 17, 1974
成立日期1931
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Jacob Martin Wiborg Rode
Mr. Jacob Martin Wiborg Rode
Head of Investor Relations
Head of Investor Relations
--
--
Ms. Thilde Hummel Bogebjerg
Ms. Thilde Hummel Bogebjerg
Executive Vice President - Quality, IT & Environmental Affairs
Executive Vice President - Quality, IT & Environmental Affairs
--
--
Mr. Helge Lund
Mr. Helge Lund
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. David Moore
Mr. David Moore
Executive Vice President - US Operations and Business Development
Executive Vice President - US Operations and Business Development
--
--
Mr. Karsten Munk Knudsen
Mr. Karsten Munk Knudsen
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Mr. Thomas Rantzau
Mr. Thomas Rantzau
Director, Employee Representative
Director, Employee Representative
--
--
Ms. Tania Sabroe
Ms. Tania Sabroe
Executive Vice President - Global People, Organisation and Communication
Executive Vice President - Global People, Organisation and Communication
--
--
Dr. Martin Holst Lange
Dr. Martin Holst Lange
Executive Vice President - Development
Executive Vice President - Development
--
--
Mr. Andreas Fibig
Mr. Andreas Fibig
Independent Director
Independent Director
--
--
Dr. Sylvie L. Gregoire, Pharm.D.
Dr. Sylvie L. Gregoire, Pharm.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Jacob Martin Wiborg Rode
Mr. Jacob Martin Wiborg Rode
Head of Investor Relations
Head of Investor Relations
--
--
Ms. Thilde Hummel Bogebjerg
Ms. Thilde Hummel Bogebjerg
Executive Vice President - Quality, IT & Environmental Affairs
Executive Vice President - Quality, IT & Environmental Affairs
--
--
Mr. Helge Lund
Mr. Helge Lund
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. David Moore
Mr. David Moore
Executive Vice President - US Operations and Business Development
Executive Vice President - US Operations and Business Development
--
--
Mr. Karsten Munk Knudsen
Mr. Karsten Munk Knudsen
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Mr. Thomas Rantzau
Mr. Thomas Rantzau
Director, Employee Representative
Director, Employee Representative
--
--
收入明细
单位: USD更新时间: 4月6日 周日
单位: USD更新时间: 4月6日 周日
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
业务USD
名称
营收
占比
Total GLP-1
21.63B
51.35%
Obesity (Saxenda®)
9.45B
22.43%
Long-acting insulin
2.77B
6.58%
Fast-acting insulin
2.69B
6.38%
Rare blood disorders
1.76B
4.18%
Other
3.83B
9.08%
地区USD
名称
营收
占比
USA
24.28B
57.64%
EMEA
8.76B
20.80%
Rest of World
4.83B
11.48%
Region China
2.68B
6.37%
Canada
1.56B
3.71%
业务
地区
业务USD
名称
营收
占比
Total GLP-1
21.63B
51.35%
Obesity (Saxenda®)
9.45B
22.43%
Long-acting insulin
2.77B
6.58%
Fast-acting insulin
2.69B
6.38%
Rare blood disorders
1.76B
4.18%
Other
3.83B
9.08%
股东统计
更新时间: 4月26日 周六
更新时间: 4月26日 周六
持股股东
股东类型
持股股东
股东统计
占比
Jennison Associates LLC
0.59%
GQG Partners, LLC
0.39%
Fisher Investments
0.38%
Loomis, Sayles & Company, L.P.
0.34%
Fayez Sarofim & Co.
0.34%
Other
97.96%
持股股东
股东统计
占比
Jennison Associates LLC
0.59%
GQG Partners, LLC
0.39%
Fisher Investments
0.38%
Loomis, Sayles & Company, L.P.
0.34%
Fayez Sarofim & Co.
0.34%
Other
97.96%
股东类型
股东统计
占比
Investment Advisor
5.27%
Investment Advisor/Hedge Fund
2.93%
Research Firm
0.80%
Hedge Fund
0.63%
Pension Fund
0.28%
Insurance Company
0.21%
Bank and Trust
0.18%
Family Office
0.02%
Family Office
0.02%
Other
89.67%
机构持股
更新时间: 2月20日 周四
更新时间: 2月20日 周四
报告期
机构数
持股数
持股占比
持股变动
2025Q1
2699
351.66M
10.45%
+4.61M
2024Q4
2676
348.53M
10.35%
+330.19K
2024Q3
2529
339.29M
10.15%
-6.04M
2024Q2
2456
341.24M
10.21%
+6.87M
2024Q1
2291
330.25M
9.75%
+10.89M
2023Q4
2037
314.57M
9.30%
+1.47M
2023Q3
1826
307.14M
8.91%
+4.22M
2023Q2
1692
293.83M
8.50%
+768.69K
2023Q1
1603
284.38M
8.30%
-15.92M
2022Q4
1498
293.73M
8.57%
+2.21M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Jennison Associates LLC
19.94M
0.59%
-251.15K
-1.24%
Dec 31, 2024
GQG Partners, LLC
12.99M
0.39%
+5.56M
+74.70%
Dec 31, 2024
Fisher Investments
12.64M
0.38%
-664.99K
-5.00%
Dec 31, 2024
Loomis, Sayles & Company, L.P.
11.57M
0.34%
+2.95M
+34.18%
Dec 31, 2024
Fayez Sarofim & Co.
11.38M
0.34%
-832.64K
-6.82%
Dec 31, 2024
Fidelity Management & Research Company LLC
9.89M
0.29%
-7.78M
-44.05%
Dec 31, 2024
Managed Account Advisors LLC
9.39M
0.28%
+1.11M
+13.43%
Dec 31, 2024
Folketrygdfondet
8.90M
0.26%
+40.31K
+0.45%
Dec 31, 2024
Renaissance Technologies LLC
8.31M
0.25%
+123.68K
+1.51%
Dec 31, 2024
Capital International Investors
6.75M
0.2%
-204.59K
-2.94%
Dec 31, 2024
查看更多
持股ETF
更新时间: 4月6日 周日
更新时间: 4月6日 周日
机构名称
占比
Novo Nordisk A/S (B Shares) ADRhedged
100%
Roundhill GLP-1 & Weight Loss ETF
15.18%
Amplify Weight Loss Drug & Treatment ETF
13.08%
VanEck Pharmaceutical ETF
4.86%
iShares Long-Term US Equity Active ETF
4.59%
AdvisorShares Gerber Kawasaki ETF
4.03%
TrueShares Technology, AI & Deep Learning ETF
3.12%
Clockwise Core Equity & Innovation ETF
2.63%
PGIM Jennison Better Future ETF
2.37%
SP Funds S&P World (ex-US) ETF
2.34%
查看更多
Novo Nordisk A/S (B Shares) ADRhedged
占比100%
Roundhill GLP-1 & Weight Loss ETF
占比15.18%
Amplify Weight Loss Drug & Treatment ETF
占比13.08%
VanEck Pharmaceutical ETF
占比4.86%
iShares Long-Term US Equity Active ETF
占比4.59%
AdvisorShares Gerber Kawasaki ETF
占比4.03%
TrueShares Technology, AI & Deep Learning ETF
占比3.12%
Clockwise Core Equity & Innovation ETF
占比2.63%
PGIM Jennison Better Future ETF
占比2.37%
SP Funds S&P World (ex-US) ETF
占比2.34%
分红派息
近5年累计派现
21.09B
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
Aug 06, 2024
NVO.NB Final Cash Dividend of gross USD 0.516902 paid on Aug 26, 2024 going ex on Aug 16, 2024
Aug 16, 2024
Aug 26, 2024
Aug 16, 2024
Jan 31, 2024
NVO.NB Interim Cash Dividend of gross USD 0.929335 paid on Apr 02, 2024 going ex on Mar 22, 2024
Mar 25, 2024
Apr 02, 2024
Mar 22, 2024
Aug 10, 2023
NVO.NB Final Cash Dividend of gross USD 0.876339 paid on Aug 29, 2023 going ex on Aug 18, 2023
Aug 21, 2023
Aug 29, 2023
Aug 18, 2023
Feb 02, 2023
NVO.NB Interim Cash Dividend of gross USD 1.180581 paid on Apr 04, 2023 going ex on Mar 24, 2023
Mar 27, 2023
Apr 04, 2023
Mar 24, 2023
Aug 04, 2022
NVO.NB Final Cash Dividend of gross USD 0.577745 paid on Aug 23, 2022 going ex on Aug 12, 2022
Aug 15, 2022
Aug 23, 2022
Aug 12, 2022
Mar 02, 2022
NVO.NB Interim Cash Dividend of gross USD 1.022424 paid on Apr 05, 2022 going ex on Mar 25, 2022
Mar 28, 2022
Apr 05, 2022
Mar 25, 2022
Aug 05, 2021
NVO.NB Final Cash Dividend of gross USD 0.550289 paid on Aug 25, 2021 going ex on Aug 16, 2021
Aug 17, 2021
Aug 25, 2021
Aug 16, 2021
Feb 22, 2021
NVO.NB Interim Cash Dividend of gross USD 0.922122 paid on Apr 07, 2021 going ex on Mar 26, 2021
Mar 29, 2021
Apr 07, 2021
Mar 26, 2021
Aug 06, 2020
NVO.NB Final Cash Dividend of gross USD 0.517777 paid on Aug 25, 2020 going ex on Aug 14, 2020
Aug 17, 2020
Aug 25, 2020
Aug 14, 2020
Feb 06, 2020
NVO.NB Interim Cash Dividend of gross USD 0.782605 paid on Apr 07, 2020 going ex on Mar 27, 2020
Mar 30, 2020
Apr 07, 2020
Mar 27, 2020
拆合股
公告日期
类型
比率
Aug 14, 2023
Split
1>2
公告日期
类型
比率
Aug 14, 2023
Split
1>2